Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q7L266
UPID:
ASGL1_HUMAN
Alternative names:
Asparaginase-like protein 1; Beta-aspartyl-peptidase; Isoaspartyl dipeptidase; L-asparagine amidohydrolase
Alternative UPACC:
Q7L266; B2R7Q0; Q567Q4; Q6P1P0; Q8NI34; Q9H6F7
Background:
Isoaspartyl peptidase/L-asparaginase, known by alternative names such as Asparaginase-like protein 1 and Beta-aspartyl-peptidase, exhibits crucial enzymatic activities. It is involved in the production of L-aspartate, an excitatory neurotransmitter in the brain, and shows high activity with various beta-aspartyl dipeptides and their esters, including aspartame.
Therapeutic significance:
Understanding the role of Isoaspartyl peptidase/L-asparaginase could open doors to potential therapeutic strategies.